A citation-based method for searching scientific literature

B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh, D B Rawlins, N C Goodwin, R Mabon, B A Harrison, A Wilson, A Sands, D R Powell. Clin. Pharmacol. Ther. 2012
Times Cited: 137



David Polidori, Sue Sha, Sunder Mudaliar, Theodore P Ciaraldi, Atalanta Ghosh, Nicole Vaccaro, Kristin Farrell, Paul Rothenberg, Robert R Henry. Diabetes Care 2013
Times Cited: 161




List of shared articles



Times cited

SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy.
Jaspreet Kalra, Suresh Babu Mangali, Deepika Dasari, Audesh Bhat, Srashti Goyal, Indu Dhar, Dharamrajan Sriram, Arti Dhar. Fundam Clin Pharmacol 2020
1

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J. Clin. Endocrinol. Metab. 2020
0

Epigenetic modification and therapeutic targets of diabetes mellitus.
Rajveer Singh, Shivani Chandel, Dhritiman Dey, Arijit Ghosh, Syamal Roy, Velayutham Ravichandiran, Dipanjan Ghosh. Biosci Rep 2020
0

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari. Cardiovasc Diabetol 2019
18

What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
5


Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.
Guillermo E Umpierrez, Timothy S Bailey, Danielle Carcia, Charles Shaefer, Jay H Shubrook, Neil Skolnik. J Diabetes 2018
4


Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents.
Fuyong Du, Simon A Hinke, Cassandre Cavanaugh, David Polidori, Nathanial Wallace, Thomas Kirchner, Matthew Jennis, Wensheng Lang, Gee-Hong Kuo, Micheal D Gaul,[...]. J. Pharmacol. Exp. Ther. 2018
5



Past and current perspective on new therapeutic targets for Type-II diabetes.
Pradip D Patil, Umesh B Mahajan, Kalpesh R Patil, Sandip Chaudhari, Chandragouda R Patil, Yogeeta O Agrawal, Shreesh Ojha, Sameer N Goyal. Drug Des Devel Ther 2017
6


Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.
Panai Song, Akira Onishi, Hermann Koepsell, Volker Vallon. Expert Opin. Ther. Targets 2016
50

Sodium glucose transport modulation in type 2 diabetes and gastric bypass surgery.
Gregory Baud, Violeta Raverdy, Caroline Bonner, Mehdi Daoudi, Robert Caiazzo, François Pattou. Surg Obes Relat Dis 2016
7



Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Linda A Gallo, Ernest M Wright, Volker Vallon. Diab Vasc Dis Res 2015
120


Sodium glucose co-transporter inhibitors for the management of diabetes mellitus: an opinion paper from the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
Jennifer N Clements, Heather P Whitley, Jennifer J D'Souza, Benjamin Gross, Rick Hess, Sara Reece, Chad Gentry, Kayce Shealy. Curr Med Res Opin 2015
1

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.
Sunder Mudaliar, David Polidori, Brian Zambrowicz, Robert R Henry. Diabetes Care 2015
97